Anubha Bajaj*

Department of Histopathology, Panjab University/A.B. Diagnostics, India

*Corresponding Author: Anubha Bajaj, Department of Histopathology, Panjab University/A.B. Diagnostics, India.

Received: July 24, 2023; Published: November 18, 2023

Abstract

Cold agglutinin disease (CAD) is an exceptionally discerned haemolytic disorder configuring ~ 30% of autoimmune haemolytic anaemias (AIHA). Autoantibodies mediating cold agglutinin disease are designated as cold agglutinins (CA) as the molecules demonstrate an ability to agglutinate erythrocytes at temperatures beneath central body temperature.

References

1. Berentsen S., et al. “Cold Agglutinin Disease: Improved Understanding of Pathogenesis Helps Define Targets for Therapy”.Hemato4 (2022): 574-594.
2. Suzuki Y and Shiba T. “Chronic cold agglutinin disease after a third COVID-19 mRNA vaccination”. International Journal of Hematology 4 (2023): 618-621.
3. Joly F., et al. “The Burden of Cold Agglutinin Disease on Patients' Daily Life: Web-Based Cross-sectional Survey of 50 American Patients”. JMIR Form Research7 (2022): e34248.
4. Hansen DL., et al. “Mortality in cold agglutinin disease shows seasonal pattern”. Transfusion 7 (2022): 1460-1461.
5. Nakagawa H., et al. “Necrosis secondary to cold agglutinin disease”. CMAJ 14 (2022): E528.
6. Image 1 Courtesy: Medbullets.com.
7. Image 2 Courtesy: MDPI.com.

Citation

Citation: Anubha Bajaj. “Algid and Hindered-Cold Agglutinin Disease".Acta Scientific Biotechnology 4.4 (2023): 37-40.

Copyright

Copyright: © 2023 Anubha Bajaj. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.